Recursion discreetly culls a rare disease program to focus on cancer, pulls in $150M private placement
25 Oct 2022
Recursion Pharmaceuticals quietly shut down work on one of its clinical programs Tuesday.
Researchers will end development on REC-3599, a drug candidate for GM2 gangliosidosis, the Salt Lake City biotech said in SEC filings Tuesday. Recursion CEO Chris Gibson told
Endpoints News
that the move will help the company focus more on its oncology work.
“We were in a position where that program was going to read out very likely much, much later than any of the other programs in our pipeline,” Gibson said. “That meant that something had to come out of the funnel, and for us it was a program that’s further on the horizon.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.